| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.02 |